Every 10-Q that Neuropace, Inc. (NPCE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NPCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NPCE filings page.
NeuroPace, Inc. reported higher sales but continued losses for the quarter ended June 30, 2026. Revenue rose to $22.8 million from $19.5 million a year earlier (up 17%), driven by more RNS System initial implants and replacements. Gross margin remained high at 82.8%, little changed from 83.1%.
Operating expenses were stable overall, with higher sales and marketing spending offset by lower general and administrative costs after prior one-time severance and transition charges. Net loss from continuing operations narrowed to $6.2 million in the quarter and $12.9 million for the first half, compared with $10.0 million and $18.2 million, respectively, in 2025.
Cash, cash equivalents and short‑term investments totaled $51.7 million at June 30, 2026, with net cash used in operating activities of $9.8 million in the first half. Long‑term debt under the MidCap term loan was $59.0 million. The company remained in compliance with liquidity and revenue covenants, supported by $89.2 million in trailing 12‑month net RNS System revenue. NeuroPace also determined its DIXI Medical product line qualifies as a discontinued operation and ceased related sales, simplifying its focus on the RNS System. The FDA, however, informed the company that its Premarket Approval Supplement for a generalized epilepsy label expansion is not approvable in its current form and requested additional information.
NeuroPace, Inc. reported first‑quarter 2026 revenue of $22.1 million, slightly below the prior year as DIXI distribution revenue rolled off but RNS System unit volumes increased. Gross margin improved to 81.8% as higher‑margin RNS sales replaced lower‑margin distributed products.
The company posted a net loss of $6.7 million, or $0.20 per share, similar to the prior‑year loss. Cash, cash equivalents and short‑term investments totaled $54.0 million, with $59.0 million of term debt outstanding under its MidCap facility, and management believes liquidity supports at least 12 months of operations while remaining in covenant compliance.
NeuroPace is exiting its DIXI Medical distribution agreement, expects to treat it as discontinued operations once remaining inventory is returned, and continues to pursue label expansion for its RNS System, including idiopathic generalized and pediatric focal epilepsy indications, alongside ongoing investments in R&D and commercial expansion.
NeuroPace, Inc. (NPCE) reported Q3 2025 results with revenue of $27,354,000 versus $21,060,000 a year ago, reflecting strong year-over-year growth. Gross profit was $21,168,000, and the company recorded a net loss of $3,496,000 compared to a $5,452,000 loss in Q3 2024. Year-to-date, revenue reached $73,398,000 with a net loss of $18,736,000.
As of September 30, 2025, cash, cash equivalents and short-term investments totaled $60,000,000. Long-term debt was $58,748,000 after the June refinancing that repaid the CRG term loan and established a new MidCap term loan maturing in 2030. The company completed a February follow-on offering of 7,475,000 shares at $10.00 per share for net proceeds of $69,700,000 and used $49,500,000 to repurchase 5,270,845 shares from a significant stockholder at $9.40 per share.
Management states compliance with MidCap liquidity and revenue covenants, with trailing 12‑month RNS System net revenue of $77,000,000 as of September 30, 2025. The DIXI Medical U.S. distribution agreement expired on September 30, 2025 and is in a six‑month wind‑down period.
NeuroPace reported sequentially stronger commercial results with improving margins but continued net losses and new financing activity that reshaped its balance sheet. Revenue for the quarter was $23.5 million, up 22% from the year-ago quarter, producing gross profit of $18.1 million and a gross margin of 77.1% versus 73.4% a year earlier. The company recorded a net loss of $8.7 million ($0.26 per share) for the quarter and a six-month net loss of $15.2 million.
NeuroPace ended June 30, 2025 with $62.1 million of cash, cash equivalents and short-term investments. In February 2025 it completed a follow-on offering that generated $69.7 million net proceeds and used $49.5 million to repurchase shares from a significant stockholder. In June 2025 NeuroPace replaced its prior CRG term loan with a $60.0 million MidCap term loan and had $58.6 million of long-term debt, net. The company remains in compliance with its MidCap covenants, reporting trailing 12-month RNS System revenue of $71.6 million and stating its cash resources are expected to fund operations for at least 12 months.